Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010.
Identifieur interne : 000472 ( Main/Exploration ); précédent : 000471; suivant : 000473Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010.
Auteurs : D M Skowronski [Canada] ; G. De Serres ; N Z Janjua ; J L Gardy ; V. Gilca ; M. Dionne ; M E Hamelin ; C. Rhéaume ; G. BoivinSource :
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [ 1560-7917 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Animaux (MeSH), Anticorps antiviraux (biosynthèse), Anticorps antiviraux (métabolisme), Canada (épidémiologie), Données de séquences moléculaires (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Femelle (MeSH), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Nourrisson (MeSH), Réactions croisées (immunologie), Sous-type H3N2 du virus de la grippe A (immunologie), Suidae (MeSH), Séquence d'acides aminés (MeSH), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (usage thérapeutique), Vaccins inactivés (immunologie), Vaccins inactivés (usage thérapeutique).
- MESH :
- biosynthèse : Anticorps antiviraux.
- immunologie : Grippe humaine, Réactions croisées, Sous-type H3N2 du virus de la grippe A, Vaccins antigrippaux, Vaccins inactivés.
- métabolisme : Anticorps antiviraux.
- prévention et contrôle : Grippe humaine.
- usage thérapeutique : Vaccins antigrippaux, Vaccins inactivés.
- épidémiologie : Canada, Grippe humaine.
- Adulte, Adulte d'âge moyen, Animaux, Données de séquences moléculaires, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Jeune adulte, Mâle, Nourrisson, Suidae, Séquence d'acides aminés.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adult (MeSH), Amino Acid Sequence (MeSH), Animals (MeSH), Antibodies, Viral (biosynthesis), Antibodies, Viral (metabolism), Canada (epidemiology), Child (MeSH), Child, Preschool (MeSH), Cross Reactions (immunology), Female (MeSH), Humans (MeSH), Infant (MeSH), Influenza A Virus, H3N2 Subtype (immunology), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (prevention & control), Male (MeSH), Middle Aged (MeSH), Molecular Sequence Data (MeSH), Swine (MeSH), Vaccines, Inactivated (immunology), Vaccines, Inactivated (therapeutic use), Young Adult (MeSH).
- MESH :
- chemical , biosynthesis : Antibodies, Viral.
- chemical , immunology : Influenza Vaccines, Vaccines, Inactivated.
- chemical , metabolism : Antibodies, Viral.
- geographic , epidemiology : Canada.
- epidemiology : Influenza, Human.
- immunology : Cross Reactions, Influenza A Virus, H3N2 Subtype, Influenza, Human.
- prevention & control : Influenza, Human.
- chemical , therapeutic use : Influenza Vaccines, Vaccines, Inactivated.
- Adult, Amino Acid Sequence, Animals, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Molecular Sequence Data, Swine, Young Adult.
Abstract
In pre- and post-immunisation sera from children (17-120 months-old) and adults (20-59 years-old) immunised with 2010/11 trivalent inactivated influenza vaccine, we assessed age-related patterns of sero-susceptibility and vaccine-induced cross-reactive antibodies to a representative swine H3N2 (swH3N2) and a related ancestral human H3N2 (A/Sydney/5/1997) influenza virus. Few children but a greater proportion of adults showed pre-immunisation haemagglutination inhibition titres ≥40 to either virus. Titres increased with age among children but decreased in adults. Fewer than 20% showed a four-fold rise in antibody titres to either virus following immunisation. Further investigation is warranted to guide ongoing risk assessment and response to emerging swine H3N2 viruses.
DOI: 10.2807/ese.17.04.20066-en
PubMed: 22297136
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010.</title><author><name sortKey="Skowronski, D M" sort="Skowronski, D M" uniqKey="Skowronski D" first="D M" last="Skowronski">D M Skowronski</name><affiliation wicri:level="3"><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver, Canada. danuta.skowronski@@bccdc.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>British Columbia Centre for Disease Control, Vancouver</wicri:regionArea><placeName><settlement type="city">Vancouver</settlement><region type="state">Colombie-Britannique</region></placeName></affiliation></author><author><name sortKey="De Serres, G" sort="De Serres, G" uniqKey="De Serres G" first="G" last="De Serres">G. De Serres</name></author><author><name sortKey="Janjua, N Z" sort="Janjua, N Z" uniqKey="Janjua N" first="N Z" last="Janjua">N Z Janjua</name></author><author><name sortKey="Gardy, J L" sort="Gardy, J L" uniqKey="Gardy J" first="J L" last="Gardy">J L Gardy</name></author><author><name sortKey="Gilca, V" sort="Gilca, V" uniqKey="Gilca V" first="V" last="Gilca">V. Gilca</name></author><author><name sortKey="Dionne, M" sort="Dionne, M" uniqKey="Dionne M" first="M" last="Dionne">M. Dionne</name></author><author><name sortKey="Hamelin, M E" sort="Hamelin, M E" uniqKey="Hamelin M" first="M E" last="Hamelin">M E Hamelin</name></author><author><name sortKey="Rheaume, C" sort="Rheaume, C" uniqKey="Rheaume C" first="C" last="Rhéaume">C. Rhéaume</name></author><author><name sortKey="Boivin, G" sort="Boivin, G" uniqKey="Boivin G" first="G" last="Boivin">G. Boivin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22297136</idno><idno type="pmid">22297136</idno><idno type="doi">10.2807/ese.17.04.20066-en</idno><idno type="wicri:Area/Main/Corpus">000472</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000472</idno><idno type="wicri:Area/Main/Curation">000472</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000472</idno><idno type="wicri:Area/Main/Exploration">000472</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010.</title><author><name sortKey="Skowronski, D M" sort="Skowronski, D M" uniqKey="Skowronski D" first="D M" last="Skowronski">D M Skowronski</name><affiliation wicri:level="3"><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver, Canada. danuta.skowronski@@bccdc.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>British Columbia Centre for Disease Control, Vancouver</wicri:regionArea><placeName><settlement type="city">Vancouver</settlement><region type="state">Colombie-Britannique</region></placeName></affiliation></author><author><name sortKey="De Serres, G" sort="De Serres, G" uniqKey="De Serres G" first="G" last="De Serres">G. De Serres</name></author><author><name sortKey="Janjua, N Z" sort="Janjua, N Z" uniqKey="Janjua N" first="N Z" last="Janjua">N Z Janjua</name></author><author><name sortKey="Gardy, J L" sort="Gardy, J L" uniqKey="Gardy J" first="J L" last="Gardy">J L Gardy</name></author><author><name sortKey="Gilca, V" sort="Gilca, V" uniqKey="Gilca V" first="V" last="Gilca">V. Gilca</name></author><author><name sortKey="Dionne, M" sort="Dionne, M" uniqKey="Dionne M" first="M" last="Dionne">M. Dionne</name></author><author><name sortKey="Hamelin, M E" sort="Hamelin, M E" uniqKey="Hamelin M" first="M E" last="Hamelin">M E Hamelin</name></author><author><name sortKey="Rheaume, C" sort="Rheaume, C" uniqKey="Rheaume C" first="C" last="Rhéaume">C. Rhéaume</name></author><author><name sortKey="Boivin, G" sort="Boivin, G" uniqKey="Boivin G" first="G" last="Boivin">G. Boivin</name></author></analytic><series><title level="j">Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</title><idno type="eISSN">1560-7917</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Amino Acid Sequence (MeSH)</term><term>Animals (MeSH)</term><term>Antibodies, Viral (biosynthesis)</term><term>Antibodies, Viral (metabolism)</term><term>Canada (epidemiology)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Cross Reactions (immunology)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Influenza A Virus, H3N2 Subtype (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Molecular Sequence Data (MeSH)</term><term>Swine (MeSH)</term><term>Vaccines, Inactivated (immunology)</term><term>Vaccines, Inactivated (therapeutic use)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Animaux (MeSH)</term><term>Anticorps antiviraux (biosynthèse)</term><term>Anticorps antiviraux (métabolisme)</term><term>Canada (épidémiologie)</term><term>Données de séquences moléculaires (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Réactions croisées (immunologie)</term><term>Sous-type H3N2 du virus de la grippe A (immunologie)</term><term>Suidae (MeSH)</term><term>Séquence d'acides aminés (MeSH)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>Vaccins inactivés (immunologie)</term><term>Vaccins inactivés (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Réactions croisées</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Cross Reactions</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Amino Acid Sequence</term><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Molecular Sequence Data</term><term>Swine</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Données de séquences moléculaires</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Suidae</term><term>Séquence d'acides aminés</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In pre- and post-immunisation sera from children (17-120 months-old) and adults (20-59 years-old) immunised with 2010/11 trivalent inactivated influenza vaccine, we assessed age-related patterns of sero-susceptibility and vaccine-induced cross-reactive antibodies to a representative swine H3N2 (swH3N2) and a related ancestral human H3N2 (A/Sydney/5/1997) influenza virus. Few children but a greater proportion of adults showed pre-immunisation haemagglutination inhibition titres ≥40 to either virus. Titres increased with age among children but decreased in adults. Fewer than 20% showed a four-fold rise in antibody titres to either virus following immunisation. Further investigation is warranted to guide ongoing risk assessment and response to emerging swine H3N2 viruses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22297136</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1560-7917</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Jan</Month><Day>26</Day></PubDate></JournalIssue><Title>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</Title><ISOAbbreviation>Euro Surveill.</ISOAbbreviation></Journal><ArticleTitle>Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">20066</ELocationID><Abstract><AbstractText>In pre- and post-immunisation sera from children (17-120 months-old) and adults (20-59 years-old) immunised with 2010/11 trivalent inactivated influenza vaccine, we assessed age-related patterns of sero-susceptibility and vaccine-induced cross-reactive antibodies to a representative swine H3N2 (swH3N2) and a related ancestral human H3N2 (A/Sydney/5/1997) influenza virus. Few children but a greater proportion of adults showed pre-immunisation haemagglutination inhibition titres ≥40 to either virus. Titres increased with age among children but decreased in adults. Fewer than 20% showed a four-fold rise in antibody titres to either virus following immunisation. Further investigation is warranted to guide ongoing risk assessment and response to emerging swine H3N2 viruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skowronski</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>British Columbia Centre for Disease Control, Vancouver, Canada. danuta.skowronski@@bccdc.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Serres</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Janjua</LastName><ForeName>N Z</ForeName><Initials>NZ</Initials></Author><Author ValidYN="Y"><LastName>Gardy</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Gilca</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Dionne</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hamelin</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Rhéaume</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Boivin</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Euro Surveill</MedlineTA><NlmUniqueID>100887452</NlmUniqueID><ISSNLinking>1025-496X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22297136</ArticleId><ArticleId IdType="doi">10.2807/ese.17.04.20066-en</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Colombie-Britannique</li></region><settlement><li>Vancouver</li></settlement></list><tree><noCountry><name sortKey="Boivin, G" sort="Boivin, G" uniqKey="Boivin G" first="G" last="Boivin">G. Boivin</name><name sortKey="De Serres, G" sort="De Serres, G" uniqKey="De Serres G" first="G" last="De Serres">G. De Serres</name><name sortKey="Dionne, M" sort="Dionne, M" uniqKey="Dionne M" first="M" last="Dionne">M. Dionne</name><name sortKey="Gardy, J L" sort="Gardy, J L" uniqKey="Gardy J" first="J L" last="Gardy">J L Gardy</name><name sortKey="Gilca, V" sort="Gilca, V" uniqKey="Gilca V" first="V" last="Gilca">V. Gilca</name><name sortKey="Hamelin, M E" sort="Hamelin, M E" uniqKey="Hamelin M" first="M E" last="Hamelin">M E Hamelin</name><name sortKey="Janjua, N Z" sort="Janjua, N Z" uniqKey="Janjua N" first="N Z" last="Janjua">N Z Janjua</name><name sortKey="Rheaume, C" sort="Rheaume, C" uniqKey="Rheaume C" first="C" last="Rhéaume">C. Rhéaume</name></noCountry><country name="Canada"><region name="Colombie-Britannique"><name sortKey="Skowronski, D M" sort="Skowronski, D M" uniqKey="Skowronski D" first="D M" last="Skowronski">D M Skowronski</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000472 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000472 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22297136
|texte= Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22297136" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |